“…In our cohort, we have demonstrated rates of ROSC and 30-day survival that are numerically higher than previously published cohorts of survival after IHCA in COVID-19, but lower than recent studies of IHCA prior to COVID-19, which demonstrated rates of ROSC of 54–64% and survival of 22–28%. 8 , 9 , 10 , 19 , 20 Since early in the pandemic there has been speculation about poor outcomes from resuscitation of patients with COVID-19. 6 , 21 These concerns have been further validated by recent studies that described the clinical outcomes of IHCA in COVID-19.…”